» Articles » PMID: 30175132

Mutation Study of Malaysian Patients with Ornithine Transcarbamylase Deficiency: Clinical, Molecular, and Bioinformatics Analyses of Two Novel Missense Mutations of the Gene

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2018 Sep 4
PMID 30175132
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Ornithine transcarbamylase deficiency (OTCD), an X-linked disorder that results from mutations in the gene, causes hyperammonemia and leads to various clinical manifestations. Mutations occurring close to the catalytic site of OTCase can cause severe OTCD phenotypes compared with those caused by mutations occurring on the surface of this protein. In this study, we report two novel missense mutations, Q171H and N199H, found in Malaysian patients. Q171H and N199H caused neonatal onset OTCD in a male and late OTCD in a female, respectively. In silico predictions and molecular docking were performed to examine the effect of these novel mutations, and the results were compared with other 30 known mutations. In silico servers predicted that Q171H and N199H, as well as 30 known missense mutations, led to the development of OTCD. Docking analysis indicated that N-(phosphonoacetyl)-L-ornithine (PALO) was bound to the catalytic site of OTCase mutant structure with minimal conformational changes. However, the mutations disrupted interatomic interactions in the catalytic site. Therefore, depending on the severity of disruption occurring at the catalytic site, the mutation may affect the efficiency of mechanism and functions of OTCase.

Citing Articles

Pathogenic variants of ornithine transcarbamylase deficiency: Nation-wide study in Japan and literature review.

Kido J, Sugawara K, Sawada T, Matsumoto S, Nakamura K Front Genet. 2022; 13:952467.

PMID: 36303552 PMC: 9593096. DOI: 10.3389/fgene.2022.952467.


A preliminary investigation of amino acid and acylcarnitine levels in neonates from the Tibet autonomous.

Zhang C, Dha D, Cheng Y, Ma Y, Meng Y, Tse D Front Genet. 2022; 13:941938.

PMID: 36299584 PMC: 9589887. DOI: 10.3389/fgene.2022.941938.

References
1.
Tuchman M, Morizono H, Rajagopal B, Plante R, Allewell N . The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J Inherit Metab Dis. 1998; 21 Suppl 1:40-58. DOI: 10.1023/a:1005353407220. View

2.
Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H . Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. J Genet Genomics. 2015; 42(5):181-94. PMC: 4565140. DOI: 10.1016/j.jgg.2015.04.003. View

3.
Auton A, Brooks L, Durbin R, Garrison E, Kang H, Korbel J . A global reference for human genetic variation. Nature. 2015; 526(7571):68-74. PMC: 4750478. DOI: 10.1038/nature15393. View

4.
McCullough B, Yudkoff M, Batshaw M, Wilson J, Raper S, Tuchman M . Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet. 2000; 93(4):313-9. DOI: 10.1002/1096-8628(20000814)93:4<313::aid-ajmg11>3.0.co;2-m. View

5.
Foschi F, Morelli M, Savini S, DallAglio A, Lanzi A, Cescon M . Urea cycle disorders: a case report of a successful treatment with liver transplant and a literature review. World J Gastroenterol. 2015; 21(13):4063-8. PMC: 4385556. DOI: 10.3748/wjg.v21.i13.4063. View